Edison Investment Research - Deinove S.A. (ALDEI) Deinove - Phase II study with DNV3837 for C. diff starts

Report

Edison Investment Research

Sean Conroy

Deinove - Phase II study with DNV3837 for C. diff starts

Deinove reported that the first patient has been enrolled in its Phase II study with a novel quinolonyl-oxazolidinone class antibiotic DNV3837 for moderate to severe C. diff infections. The results are expected by the end of 2020, which will be a substantial catalyst for the share price. The company also reported multiple developments in its bioactives portfolio, including a new substantial collaboration with a partner that has experience in commercialising preservative solutions for personal care products. We have slightly increased our valuation to â‚¬78m or â‚¬4.6/share.

21/02/2020 7 EN

Underlying

Deinove S.A.

Deinove SA is a biotechnology company dedicated to the discovery, development and production of compounds based on the use of rare bacterial genus that present an interest to the health, nutrition and cosmetics sectors.

See profile

FR0010879056 Euronext Paris France

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Conversion of the receivership proceedings into judicial liquidation proceedings

Conversion of the receivership proceedings into judicial liquidation proceedings CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that on January 23, 2023, the Montpellier Commercial Court rendered a judgment converting the receivership proceedings, initiated on November 7, 2022, into a judicial liquidation proceedings (“procédure de liquidation jud...

January 24, 2023 January 24, 2023 1 EN

GlobeNewsWire

Conversion de la procédure de redressement judiciaire en liquidation judiciaire

Conversion de la procédure de redressement judiciaire en liquidation judiciaire CONVERSION DE LA PROCEDURE DE REDRESSEMENT JUDICIAIRE EN LIQUIDATION JUDICIAIRE DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que le Tribunal de Commerce de Montpellier a rendu le 23 janvier 2023 un jugement actant la conversion de la procédure de redressement judiciaire, initiée le 7 novembre 2022, en liquidation jud...

January 24, 2023 January 24, 2023 1 EN

GlobeNewsWire

DEINOVE - Update on the receivership proceedings

DEINOVE - Update on the receivership proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court met on January 13, 2023 to examine the case and reserved its decision until January 23, 2023. The listing of the Company's shares (ISIN: FR0010879056), which has been suspended sin...

January 16, 2023 January 16, 2023 1 EN

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

1h / 6m 1h / 6m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

18h / 45m 18h / 45m 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

21h / 34m 21h / 34m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Deinove - Phase II study with DNV3837 for C. diff starts

Conversion of the receivership proceedings into judicial liquidation proceedings

Conversion de la procédure de redressement judiciaire en liquidation judiciaire

DEINOVE - Update on the receivership proceedings

Biodexa Pharmaceuticals - In a period of transition

Norcros - Sale of Johnson Tiles UK agreed

Henderson Far East Income - Repositioning to raise total returns

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe